Bionano Genomics, Inc.
BNGOOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M |
| Operating income | −$33.3M | −$104.0M | −$215.2M | −$131.7M | −$77.1M | −$38.6M |
| Net income | −$26.4M | −$112.0M | −$232.5M | −$132.6M | −$72.4M | −$41.1M |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M | $60.5M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M | $25.4M |
| Equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M | $35.1M |
| EPS (diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 | — |
| Shares out. | 3.0M | 54.7M | 306.2M | 289.6M | 278.7M | 37.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −116.9%
- Net margin
- −92.6%
- Return on equity
- −59.4%
- Return on assets
- −35.9%
- Return on capital (ROCE)
- −65.8%
- Liabilities / assets
- 39.6%
- Debt / equity
- 0.66×
- Book value / share
- $14.77
- Revenue growth (YoY)
- −7.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -31.33distress
- Accruals / assets
- −13.7%clean
- Beneish M-Score
- -3.48normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chaubey AlkaOfficer — CHIEF MEDICAL OFFICER | Feb 17, 2026 | Tax withholding | 18 | $1.10 |
| Adamchak MarkOfficer — Principal Accounting Officer | Feb 17, 2026 | Tax withholding | 3 | $1.10 |
| Dixon Jonathan V.Officer — GENERAL COUNSEL | Feb 17, 2026 | Tax withholding | 6 | $1.10 |
| Oldakowski MarkOfficer — CHIEF OPERATING OFFICER | Feb 17, 2026 | Tax withholding | 20 | $1.10 |
| Holmlin R. ErikOfficer — PRESIDENT AND CEO | Feb 17, 2026 | Tax withholding | 51 | $1.10 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.2M | 6.5 | +8.7% |
| Apr 30, 2026 | 1.1M | 9.8 | -1.6% |
| Apr 15, 2026 | 1.1M | 9.1 | -7.3% |
| Mar 31, 2026 | 1.2M | 1.2 | +13.3% |
| Mar 13, 2026 | 1.1M | 10.5 | -6.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 28, 2026
- Shareholder voteMay 14, 2026
- Results of operationsMay 13, 2026
- Director / officer change · Other material eventMay 6, 2026
- Results of operationsMar 23, 2026
- Results of operationsJan 12, 2026
- Results of operationsNov 13, 2025
- Entered a material agreement · Other material eventSep 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.